CAM
IRON icon

Cormorant Asset Management’s Disc Medicine IRON Stock Holding History

Cormorant Asset Management’s Portfolio IRON Stock Details IRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-125,000
Closed -$7.78M – 59
2024
Q1 		$7.78M Hold
125,000
– – 0.34% 49
2023
Q4 		$7.22M Sell
125,000
-100,000
-44% -$5.12M 0.34% 38
2023
Q3 		$10.6M Hold
225,000
– – 0.62% 34
2023
Q2 		$9.99M Buy
+225,000
New +$7.98M 0.56% 39
2021
Q2 		– Sell
-15,833
Closed -$6.44M – 114
2021
Q1 		$6.44M Buy
+15,833
New +$7.06M 0.14% 87

Other funds holding IRON

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Cormorant Asset Management's IRON Position: Q2 2024 in Review

Cormorant Asset Management sold out of Disc Medicine (IRON) in Q2 2024, closing a stake of 125,000 shares — an estimated $7.78M sold.

Cormorant Asset Management first reported a position in IRON in Q1 2021 and held it in 5 quarters. The position peaked at $10.6M in Q3 2023. 121 funds tracked by Wall St. Rank hold IRON as of Q2 2024.

  • Cormorant Asset Management reported no remaining Disc Medicine position as of Q2 2024 after selling out during the quarter.
  • Cormorant Asset Management sold 125,000 Disc Medicine shares in Q2 2024, an estimated $7.78M.
  • Cormorant Asset Management first reported a position in Disc Medicine in Q1 2021 and held it in 5 quarters.
  • Cormorant Asset Management's Disc Medicine position peaked at $10.6M in Q3 2023.
  • 121 funds tracked by Wall St. Rank held Disc Medicine as of Q2 2024.

Based on Cormorant Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.